eyeforpharma The Marketing Disruption Summit

eyeforpharma2 - 3 October 2019, Philadelphia, USA.
It's 2019 and Marketing is changing. Your customers' expectations have shifted to ‘one-click’. They expect more, they’re used to intuitive consumer interactions, and now they're looking at pharma.

Providing the seamless, personalized experience you've been dreaming about has never seemed closer. But marketers can't do it alone.

The Marketing Disruption Summit attendance is already ahead of expectations, with groups of industry leaders from across Marketing, Strategy, Data and IT already booked to delve deep into specifics with talks, workshops and case studies from top pharma, and equip themselves to be the key changemakers at home.

On current predictions, tickets will sell out this year. Ensure you have a place reserved at the only event where pharma marketing, data & IT change makers redefine customer interaction.

Reach out like never before

With Industry Leading Speakers carefully selected to cover every aspect of the back and front-end customer cycle, and an agenda designed to provide solutions to all the collaborative problems holding back your customer engagement:

Including:

  • Martina Flammer SVP customer value, Boehringer Ingelheim
  • Krishna Cheriath Chief Data Officer BMS
  • Alessandra Almeida Snr Director, Global Head of Master Data Management, Sanofi
  • Ignacio Quiles lara exec director global marketing and commercial ops, Abbvie
  • Ramon Vega head of global pharma marketing IT, Merck
  • Renaud Sermondade Head of insights and analytics, Sanofi

Unite to exceed changing customer demands

Marketers: Understand the technical capabilities within your business, build results-based strategies, and unite teams behind your vision.

Data: Communicate your capabilities and gain vital authority in strategic conversations.

Technology: Show stakeholders what your internal teams can do and inspire new strategies with innovation.

Together: Build cross functional strategies to revolutionize, personalize and redefine customer interaction.

World Pharma News readers can benefit from an exclusive discount, just use the code WPN300 to save $300 when you register here

For further information, please visit:
https://www.eyeforpharma.com/marketingusa/

About eyeforpharma

Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...